Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
AssigneesAstellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
InventorsUgur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
Life of this patent
Estimating the term…
Abstract
The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
Claims20
A method of treating pancreatic cancer in a patient in need thereof, wherein the pancreatic cancer is characterized by cells expressing claudin 18 splice variant 2 (CLDN18.2), the method comprising:
- administering an anti-CLDN18.2 antibody to the patient, wherein the antibody comprises a heavy chain variable region (VH) having an amino acid sequence represented by SEQ ID NO:
- 32 and a light chain variable region (VL) having an amino acid sequence represented by SEQ ID NO:
- 39, and wherein the antibody has the ability of binding to CLDN18.2 and mediates killing of cells expressing CLDN18.2;
- administering gemcitabine to the patient to increase susceptibility of the cells to killing by the anti-CLDN18.2 antibody;
- and
- administering a taxane to the patient.
A method of treating metastatic pancreatic carcinoma in a patient in need thereof, wherein the pancreatic carcinoma is characterized by cells expressing claudin 18 splice variant 2 (CLDN18.2), the method comprising:
- administering an anti-CLDN18.2 antibody to the patient, wherein the antibody comprises a heavy chain variable region (VH) having an amino acid sequence represented by SEQ ID NO:
- 32 and a light chain variable region (VL) having an amino acid sequence represented by SEQ ID NO:
- 39, and wherein the antibody has the ability of binding to CLDN18.2 and mediates killing of cells expressing CLDN18.2;
- and
- administering a combination of chemotherapeutic agents to the patient, wherein the combination comprises gemcitabine and a taxane and wherein the combination stabilizes or increases expression of CLD18.2.
Dependencies are inferred from the claim text.